دورية أكاديمية
Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling.
| العنوان: | Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling. |
|---|---|
| المؤلفون: | Oury, Cécile, MARECHAL, Patrick, Donis, Nathalie, Hulin, Alexia, Hego, Alexandre, TRIDETTI, Julien, Nguyen, Mai-Linh, DULGHERU, Raluca Elena, Fillet, Marianne, Nchimi Longang, Alain, Lancellotti, Patrizio |
| المصدر: | International Journal of Molecular Sciences, 21 (11) (2020) |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute (MDPI) |
| سنة النشر: | 2020 |
| المجموعة: | University of Liège: ORBi (Open Repository and Bibliography) |
| مصطلحات موضوعية: | metabolism, rabbit model, serotonergic drugs, valvular heart disease, Human health sciences, Cardiovascular & respiratory systems, Sciences de la santé humaine, Systèmes cardiovasculaire & respiratoire |
| الوصف: | peer reviewed ; Several clinical reports indicate that the use of amphetaminic anorectic drugs or ergot derivatives could cause valvular heart disease (VHD). We sought to investigate whether valvular lesions develop in response to long-term oral administration of these drugs and to identify drug-targeted biological processes that may lead to VHD. Treatment of New Zealand White rabbits with pergolide, dexfenfluramine, or high-dose serotonin for 16 weeks induced valvular alterations characterized by extracellular matrix remodeling. Transcriptome profiling of tricuspid valves using RNA sequencing revealed distinct patterns of differentially expressed genes (DEGs) that clustered according to the different treatments. Genes that were affected by the three treatments were functionally enriched for reduced cell metabolism processes. The two drugs yielded more changes in gene expression than serotonin and shared most of the DEGs. These DEGs were mostly enriched for decreased biosynthetic processes, increased cell-matrix interaction, and cell response to growth factors, including TGF-β, which was associated with p38 MAPK activation. Treatment with pergolide specifically affected genes involved in homeostasis, which was corroborated by the activation of the master regulator of cell energy homeostasis, AMPK-α, as well as decreased levels of metabolism-related miR-107. Thus, both pergolide and dexfenfluramine may cause VHD through valve metabolic reprogramming and matrix remodeling. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1661-6596 1422-0067 |
| العلاقة: | urn:issn:1661-6596; urn:issn:1422-0067; https://orbi.uliege.be/handle/2268/249180Test; info:hdl:2268/249180; https://orbi.uliege.be/bitstream/2268/249180/1/ijms-21-04003.pdfTest; scopus-id:2-s2.0-85086027596; info:pmid:32503311 |
| DOI: | 10.3390/ijms21114003 |
| الإتاحة: | https://doi.org/10.3390/ijms21114003Test https://orbi.uliege.be/handle/2268/249180Test https://orbi.uliege.be/bitstream/2268/249180/1/ijms-21-04003.pdfTest |
| حقوق: | open access ; http://purl.org/coar/access_right/c_abf2Test ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.ACD67EF9 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 16616596 14220067 |
|---|---|
| DOI: | 10.3390/ijms21114003 |